GlobeNewswire by notified

Interim Report for the period 1 January – 30 September 2023


The Supervisory Board of Tivoli A/S has adopted the Interim Report for the period 1 January – 30 September 2023.

Results for the period 1 January – 30 September 2023 in outline:

  • A revenue of DKK 845.4 million compared to DKK 773.3 million last year (+9%).
  • An EBITDA of DKK 126.0 million compared to DKK 132.6 million last year.
  • A profit before tax of DKK 38.1 million compared to DKK 41.1 million last year.
  • An attendance figure of 2,694,000 visitors compared to 2,502,000 last year (+8%).

The first months of 2023 saw extensive maintenance and preparation work ahead of the start of the season at the end of March and was followed by a well-attended summer season. The summer has given Tivoli and the experience industry in general several challenges; July had a record-breaking rainfall and the two major neighboring markets, Sweden and Norway, caused a significant decrease in the number of guests due to their weakened economy and purchasing power. Despite these conditions, the number of guests for the period 1 January to 30 September 2023 was 2,694,000, which is 8% higher than the same period last year, aided by seven extra days open.

“Tivoli has experienced solid progress in its business, and the summer of 2023 has produced the best profits in Tivoli's history. There is still uncertainty about the macroeconomic developments and how developments in our neighboring countries will affect the proportion of tourists from the larger neighboring markets for the rest of the year. Tivoli's business is well equipped however, based on the winter's investments, a successful summer season and a great opening of Halloween in Tivoli, for a strong end to 2023 with a well-planned Christmas season, which includes a new, spectacular ice rink” says CEO, Susanne Mørch Koch.

Outlook for 2023
Tivoli’s good start to 2023 has continued through the summer season, where the consumption-related slowdown has been less than expected. Tivoli's most recent expectation was revenue around 1,150 million DKK and a profit before tax in the range of 70-90 million DKK. As a result of the summer's record high revenue and profit, as well as the expectations for the rest of the year, Tivoli is now raising the expectations to revenue around DKK 1,200 million DKK and a profit before tax in the range of DKK 100 million DKK.

Best regards

Tom Knutzen            Susanne Mørch Koch
Chairman                CEO

Contact person: Head of press, Torben Plank phone 22237440 /


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Dassault Aviation Wins Choiseul “Strategic Company” Award29.11.2023 10:21:57 CET | Press release

Dassault Aviation Wins Choiseul “Strategic Company” Award (Saint-Cloud, November 29, 2023) – Dassault Aviation is particularly proud to have received the 2023 Strategic Company Award as part of the Institut Choiseul’s Sovereignty Initiative. The institute believes that strategic companies represent one of the many facets of national strength. Award recipients are known for their capacity to effectively mobilize resources and know-how, and to provide solutions that meet national priorities. They are a cornerstone of French strategic heritage. Dassault Aviation is an industrial architect and complex systems integrator, a developer of strategic technologies, a major national exporter, a core shareholder of the Thales Group and a vital player in an industrial landscape that includes hundreds of business and service partners. The company is at the core of the French sovereign defense ecosystem. Dassault Aviation is also the only non-American company that manufactures high-end business jets.

Company announcement no 17/2023 Interim Report Q3 202329.11.2023 10:20:00 CET | Press release

Interim Report Q3 2023 EBITDA fixed herd prices (FHP) for Q3 2023 increased to 13.663 mEUR (Q3 2022: 10.463 kEUR), corresponding to an EBITDA margin FHP of 36.3% (Q3 2022: 32.5%). The quarterly EBITDA in Q3 2023 increased by 3.201 kEUR (compared to Q3 2022). Nevertheless, this consist of many parts this quarter: Russia harvest negative with 2,7 mEUR (from 4,1 to 1,5 mEUR) whereas remaining Russian business compensate positive with 3,0 mEUR partly due to FX (cost in EUR lower), Lithuania negative effects from one-off subsidy in Q3 2022 (2,5 mEUR), but combined sales/feed with positive effect of 4.9 mEUR and lower cost levels with 0.5 mEUR driven by utilities. Sales prices combined down, as they in Q3 2023 were 1.59 EUR/kg live weight, down from 1.62 EUR/kg Q2 2022 equal to EUR 0,8m, but EURRUB effects this picture highly as Lithuanian sales prices in EUR is up 23% and Russian in RUB is up 13%. Feed prices in Q3 2023 were 261 EUR/T (compared to 332 EUR/T Q3 2022). End September 2023 on h

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®29.11.2023 10:00:00 CET | Press release

The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study, which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects, met its primary endpoints. “These results demonstrate the strength of our platform approach to biosimilars development and manufacture, combining a well-designed and executed clinical study with the design of a high-quality manufacturing process and strong analytical capabilities,” said Joseph McClellan, Chief Scientific Officer. “As we progress more biosimilar candidates through clinical development and approval, w